Your browser doesn't support javascript.
loading
[Sustaining molecular response with very low dose ponatinib and further response after hemodialysis initiation in a patient with chronic myeloid leukemia].
Sato, Keijiro; Sumi, Masahiko; Kobayashi, Mamoru; Kataoka, Keisuke; Takahashi, Naoto; Kobayashi, Hikaru.
Affiliation
  • Sato K; Department of Hematology, Nagano Red Cross Hospital.
  • Sumi M; Department of Hematology, Nagano Red Cross Hospital.
  • Kobayashi M; Department of Nephrology, Nagano Red Cross Hospital.
  • Kataoka K; Department of Hematology, Keio University School of Medicine.
  • Takahashi N; Department of Hematology, Nephrology, and Rheumatology, Akita University School of Medicine.
  • Kobayashi H; Department of Hematology, Nagano Red Cross Hospital.
Rinsho Ketsueki ; 64(10): 1266-1269, 2023.
Article in Ja | MEDLINE | ID: mdl-37914238
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Antineoplastic Agents Limits: Aged / Humans / Male / Middle aged Language: Ja Journal: Rinsho Ketsueki Year: 2023 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Antineoplastic Agents Limits: Aged / Humans / Male / Middle aged Language: Ja Journal: Rinsho Ketsueki Year: 2023 Document type: Article Country of publication: